1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplalin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996
2. Updated analysis shows highly significant improved overall survival (OS) for cisplatinpaclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC-CTG and Scottish intergroup trial;Stuart;Proc Am Soc Clin Oncol,1998
3. Cisplalin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial;du Bois;Proc Am Soc Clin Oncol,1999
4. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) vs carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC). A Gynecologic Oncology Group trial (GOG 158);Ozols;Proc Am Soc Clin Oncol,1999
5. Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population;Markman;J Clin Oncol,1992